- Home
- BHC vs HTFL Comparison
BHC vs HTFL Comparison
Compare BHC & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BHC | HTFL |
|---|---|---|
| Founded | N/A | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.4B |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | BHC | HTFL |
|---|---|---|
| Price | $4.97 | $20.49 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $8.33 | ★ $39.20 |
| AVG Volume (30 Days) | ★ 2.5M | 1.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 423.08 | N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $8,724,000,000.00 | N/A |
| Revenue This Year | $4.48 | $40.42 |
| Revenue Next Year | N/A | $22.73 |
| P/E Ratio | $12.02 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.28 | $20.13 |
| 52 Week High | $8.69 | $41.22 |
Technical Indicators
Market Signals| Indicator | BHC | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 25.63 | 34.74 |
| Support Level | N/A | $20.13 |
| Resistance Level | $7.22 | $25.05 |
| Average True Range (ATR) | 0.20 | 1.42 |
| MACD | -0.07 | -0.06 |
| Stochastic Oscillator | 0.76 | 2.05 |
Price Performance
Historical ComparisonAbout BHC Bausch Health Companies Inc.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
About HTFL Heartflow Inc.
HeartFlow Inc is a commercial-stage medical technology company that has pioneered the use of software and AI to deliver a non-invasive solution for diagnosing and managing coronary artery disease CAD. The company operates and manages its business as one reportable and operating segment, which is the business of non-invasive coronary artery disease detection solutions. Geographically, it operates in United States, United Kingdom, Japan, and Rest of Europe, of which it derives maximum revenue from United States.